In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial dysfunction in patients with glaucoma.
San Diego, CA, June 04, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the launch of the Company’s second ocular health formula. The proprietary formula for GlaucoCetin is based on a parent compound, GlaucoHealth, which was created by Dr. Robert Ritch of the New York Eye and Ear Infirmary. GlaucoHealth was shown in an IRB-approved clinical trial to reverse mitochondrial dysfunction in the optic nerve cells of glaucoma patients. GlaucoCetin is a highly enhanced version of this parent compound.
Michael Favish, Guardion’s Chief Executive Officer, commenting on the launch of GlaucoCetin stated, “We are excited to add GlaucoCetin to our portfolio. It is the first formula designed specifically to provide enhanced retinal health and neuroprotection in eye disease patients, with a focus on the glaucoma market. The glaucoma market represents a $5.9 billion market and is growing at an estimated 3% annually. GlaucoCetin will significantly expand patient treatment options for eye doctors and Guardion’s market reach.”
Dr. Robert Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is surgeon Director Emeritus and Chief of Glaucoma Services at the New York Eye and Ear Infirmary. Dr. Ritch has devoted his career to broadening our understanding of the underlying etiologies and mechanisms of glaucoma.
Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the Securities and Exchange Commission (“SEC”) at www.sec.gov.
About Guardion Health Sciences, Inc.
Guardion is an ocular health sciences company that develops, formulates and distributes condition-specific medical foods supported by evidence-based protocols, with an initial medical food product, Lumega-Z, that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion Health Sciences, Inc. has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment.
VectorVision®, operating through a wholly-owned subsidiary of the Company, specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact: Investor Relations Contact:
Michael Favish Matthew Abenante
Chief Executive Officer Porter, LeVay & Rose, Inc.
Telephone: (212) 564-4700 Telephone: (858) 605-9055 x 201
E-mail: firstname.lastname@example.org E-mail: email@example.com